Evaluation and pharmacovigilance of projects promoting cultivation and local use of Artemisia annua for malaria
Department of Primary Health Care, University of Oxford, United Kingdom; Research Initiative for Traditional Antimalarial Methods, Oxford, United Kingdom; Department of Medical Anthropology, University of Oxford, United Kingdom; Rural Extension for Africa's Poor (REAP), PO Box 6173, Kondele, Kisumu, Kenya; Anamed Uganda, Masaka, Uganda; Anamed International, Winnenden, Germany
Background: Several non-governmental organisations (NGOs) are promoting the use of Artemisia annua teas as a home-based treatment for malaria in situations where conventional treatments are not available. There has been controversy about the effectiveness and safety of this approach, but no pharmacovigilance studies or evaluations have been published to date. Method. A questionnaire about the cultivation of A. annua, treatment of patients, and side-effects observed, was sent to partners of the NGO Anamed in Kenya and Uganda. Some of the respondents were then selected purposively for more in-depth semi-structured interviews. Results: Eighteen partners in Kenya and 21 in Uganda responded. 49% reported difficulties in growing the plant, mainly due to drought. Overall about 3,000 cases of presumed malaria had been treated with A. annua teas in the previous year, of which about 250 were in children and 54 were in women in the first trimester of pregnancy. The commonest problem observed in children was poor compliance due to the bitter taste, which was improved by the addition of sugar or honey. Two miscarriages were reported in pregnant patients. Only four respondents reported side-effects in other patients, the commonest of which was vomiting. 51% of respondents had started using A. annua tea to treat illnesses other than malaria. Conclusions: Local cultivation and preparation of A. annua are feasible where growing conditions are appropriate. Few adverse events were reported even in children and pregnant women. Where ACT is in short supply, it would make sense to save it for young children, while using A. annua infusions to treat older patients who are at lower risk. An ongoing pharmacovigilance system is needed to facilitate reporting of any adverse events. © 2011 Willcox et al; licensee BioMed Central Ltd.
antimalarial agent; sugar; Artemisia annua; article; bitter taste; child; diarrhea; drought; drug eruption; drug induced headache; drug surveillance program; feasibility study; female; first trimester pregnancy; health promotion; honey; human; interview; Kenya; malaria; male; plant breeding; pruritus; questionnaire; risk; spontaneous abortion; tea; Uganda; vomiting